ProPhase LabsPRPH -4.61% Gross Margin % is 31.51% as of Dec. 2025, which is 1% below its 10-year median of 31.79. The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 73.33% on this metric.
The historical rank and industry rank for ProPhase Labs's Gross Margin % or its related term are showing as below:
PRPH'
s Gross Margin % Range Over the Past 10 Years
Min: -2.22 Med: 31.79 Max: 57.61
Current: 31.85
During the past 13 years, the highestGross Margin % of ProPhase Labs was 57.61%. The lowest was -2.22%. And the median was 31.79%.
PRPH's Gross Margin % is ranked worse than 73.33% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs PRPH: 31.85
ProPhase Labs had a gross margin of 31.51% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for ProPhase Labs was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ProPhase Labs had a gross margin of 31.51% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ProPhase Labs Gross Margin % Related Terms
ProPhase Labs Gross Margin % Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs NSTM, IDTA, IVRO: Gross Margin % Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ProPhase Labs (PRPH) has a Gross Margin % of 31.51% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on ProPhase Labs and its competitors. This is near median its historical median of 31.79. According to the industry distribution chart, ProPhase Labs ranks #143 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 73.3%.
Is ProPhase Labs' Gross Margin % too high?
ProPhase Labs' current Gross Margin % of 31.51% is near median its 10-year median of 31.79. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. ProPhase Labs' value of 31.51% is 38.2% below this industry median. Based on the distribution chart, ProPhase Labs ranks #143 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does ProPhase Labs' Gross Margin % compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #143 out of 195 companies for Gross Margin %. This places ProPhase Labs in the lower half of its industry. The industry median Gross Margin % is 50.97. ProPhase Labs' value of 31.51% is 38.2% below this benchmark. While the company's 10-year median is 31.79 vs. the industry median of 50.97, ProPhase Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Gross Margin % of 31.51% is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Gross Margin % is 31.51%, which is near median its own 10-year median of 31.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Gross Margin % is 31.51%, which is near median its 10-year median of 31.79 and 38.2% below the Medical Diagnostics & Research industry median of 50.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Gross Margin % is 31.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 